Tozinameran for renal insufficiency, chronic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Aug 2021: Trial registered, NCT05022329
  2. 30 Sep 2021: Trial started, NCT05022329
  3. 15 Nov 2022: Trial terminated, NCT05022329
  4. 19 Feb 2025: Trial results posted, NCT05022329

The trials

NCT05022329: COVID-19 Vaccine Boosters in Patients With CKD

State
Stopped early
Phase
Phase 2 and Phase 3
People
273 taking part
Started
30 Sep 2021
Primary completion
11 May 2022
Arms
Patients who received two doses Pfizer-BioNTech vaccine, Arm 1, Patients who received two doses MODERNA vaccine, Arm 2
Results
Posted on the registry
  1. 26 Aug 2021: Trial registered
  2. 30 Sep 2021: Trial started
  3. 15 Nov 2022: Trial terminated
  4. 19 Feb 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

About the treatment

Also known as BNT162b2 vaccine (Pfizer/BioNTech), Comirnaty mrna, Pfizer-BioNTech COVID-19 Vaccine, Pfizer-BioNTech vaccine COVID-19 vaccine, Pfizer/BioNTech (BNT162b2), Tozinameran - Fractional Dose, mRNA vaccine booster, mRNA- COVID-19.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.